drugset / Trial / NCT00931073

A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers

NCT00931073

Phase 1 Completed 24 enrolled Pfizer Medivation, Inc. · collab
Non-randomizedCrossoverOpen-label

Summary

This study will evaluate the potential for a drug-drug interaction of Dimebon with ketoconazole and omeprazole, potent inhibitors of the drug metabolizing enzymes CYP3A4 and CYP2C19, respectively.

Timeline

Start
2009-07
Primary completion
2009-10
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketoconazole Small molecule 400 mg
Subject Latrepirdine Small molecule 10 mg Oral
Subject Omeprazole Other / unclassified 40 mg